You are here

Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- MRSA and pneumonia cases by ICD-9 code identification.

- Diagnosis included during inpatient stay.

- Treatment initiation in hospital.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Death of discharge within 3 days of treatment initiation.

- Exposure to other treatments with MRSA activity.

NCT01819935
Pfizer
Completed
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
NCT03329092
All Genders
18+
Years
Multiple Sites
Pneumococcal Pneumonia, Community Acquired Infections, Gram-positive Bacterial Infections
NCT00035269
All Genders
13+
Years
Multiple Sites
Pneumonia
NCT00137007
All Genders
Community-Acquired Pneumonia
NCT00360295
All Genders
16+
Years
Multiple Sites
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
Clinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
National database of inpatient admissions between January 1, 2002 and Septmeber 30, 2010
Pneumonia
  • Drug: linezolid (Zyvox)
    As prescribed-this is retrospective cohort of existing clinical data.
  • Drug: vancomycin
    As prescribed-this is retrospective cohort of existing clinical data.
  • linezolid (Zyvox)
    Intervention: Drug: linezolid (Zyvox)
  • Vancomycin
    Intervention: Drug: vancomycin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5271
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • MRSA and pneumonia cases by ICD-9 code identification.
  • Diagnosis included during inpatient stay.
  • Treatment initiation in hospital.

Exclusion Criteria:

  • Death of discharge within 3 days of treatment initiation.
  • Exposure to other treatments with MRSA activity.
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01819935
A5951163
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now